J.P. Morgan Life Sciences Private Capital
J.P. Morgan Life Sciences Private Capital is a venture capital and growth equity investment team within J.P. Morgan Asset Management, founded in late 2022 and based in New York. It invests in early-stage biotherapeutics and late-stage healthcare companies, and closed its inaugural 270 Life Sciences Private Capital Fund I with over $500 million in commitments in June 2024.
Deal activity decreased year-over-year (2 deals in the last 12 months vs 4 prior). Their most common stage is series-a (64% of deals). Average disclosed round size is $99.6M (across 11 rounds with reported amounts).
Portfolio
10
Fund Size
$500M
Top Stage
Series A
Last 12 Mo
2
Team
Anya Schiess
Managing Partner
Gaurav Gupta, MD, MSE
Managing Partner
Joseph Siletto
Managing Partner
Andrea Lisher
Managing Director
Anton Pil
Managing Director Head of Global Alternative Solutions
Barbara Smith
Managing Director Head of Human Resources
Bob Michele
Managing Director Head of Global Fixed Income, Currency & Commodities
Dan Watkins
Managing Director Chief Executive Officer APAC Head of APAC Client
Frederic Crosnier
Managing Director Head of Global Operations
John T. Donohue
Managing Director CEO AM Americas, Head of Global Liquidity
Kristian West
Managing Director Head of Investment Platform
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 ABK Biomedical | Series D | $35M | Oct 2025 |
| AAbk Biomedical Inc | Series D | $35M | Oct 2025 |
 Korsana Biosciences | Series A | $150M | Jan 2025 |
 Ottimo Pharma | Series A | $140M | Dec 2024 |
| OOttimo | Series A | $140M | Dec 2024 |
 Pathalys | Series B | $105M | Aug 2024 |
| PPathalys Pharma | Series B | $105M | Aug 2024 |
| AAverna Therapeutics | Series A | $82M | Jan 2024 |
 Averna Tx | Series A | $82M | Jan 2024 |
| AAverna | Series A | $82M | Jan 2024 |
| OOttimo | Series A | $140M | Jan 2024 |
Top Co-Investors
Last updated: 8 September 2026